Immuno-pharma company AIM ImmunoTech Inc (NYSE American:AIM) reported on Wednesday that the first subject has been dosed at Erasmus Medical Center in the Netherlands for the Phase 1b/2 DURIPANC study, evaluating Ampligen (rintatolimod) with AstraZeneca's (STO:AZN) (LON:AZN) (Nasdaq:AZN) Imfinzi (durvalumab) for late-stage pancreatic cancer.
The Phase 1b part aims to establish safety, and is expected to conclude within six months, while Phase 2 aims to determine the clinical benefit rate of the combination therapy.
Prof. Casper H.J. van Eijck, MD, PhD, pancreato-biliary surgeon at Erasmus Medical Center highlighted the potential of this combination to positively impact tumour regression and patient survival.
The study targets enrolment of up to 18 subjects in Phase 1b and up to 25 in Phase 2. The treatment regimen involves Ampligen via IV infusion twice weekly for 6 weeks, with dose escalation, and durvalumab administered every 4 weeks for up to 48 weeks or until confirmed disease progression.
TiumBio doses first patient in phase two TU2218 clinical trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Exact Sciences gains FDA approval for Cologuard Plus Test
Ferring expands gene therapy manufacturing capabilities
ImmunoPrecise subsidiary signs agreement with Biotheus for Antibody Evaluation in cancer therapy
UroGen Pharma doses first patient in Phase 3 trial of UGN-103 for bladder cancer
Immunovia announces completion of analytical validation of next-generation pancreatic cancer test
Owkin partners with AstraZeneca to Ddevelop AI Tool for gBRCA pre-screening in breast cancer
Leap Therapeutics completes enrollment for DeFianCe study evaluating DKN-01 in colorectal cancer